자폐스펙트럼장애 환자 수 분석과 예측(2026-2035년)

Autism Spectrum Disorder is a lifelong neurodevelopmental condition characterized by persistent challenges in social communication, restricted interests, repetitive behaviors, and varying levels of support needs. The prevalence of autism has increased steadily over the past two decades, largely because of enhanced awareness, improved diagnostic practices, and broader access to developmental assessments rather than a single identifiable cause. According to recent global estimates, approximately one in every 127 people worldwide was living with autism in 2021, although prevalence varies considerably between countries and regions.

Market Drivers

Increasing Autism Awareness

Growing public awareness campaigns, physician education, and school-based developmental screening programs are contributing to earlier diagnosis and increasing identification of autism across all age groups.

Improved Diagnostic Practices

Updated diagnostic guidelines, standardized assessment tools, and multidisciplinary evaluation centers are improving diagnostic accuracy and expanding the recognized patient population.

Expansion of Early Screening Programs

Routine developmental screening during early childhood is enabling earlier identification of autism, allowing patients to access intervention services at younger ages and improving long-term developmental outcomes.

Growing Epidemiological Research

National autism registries, electronic health records, and population-based surveillance programs continue improving understanding of autism prevalence, incidence, demographic distribution, and healthcare utilization worldwide.

Market Restraints

Underdiagnosis in Developing Regions

Many low- and middle-income countries continue to experience underdiagnosis because of limited specialist availability, inadequate screening programs, and lower public awareness.

Regional Variability in Diagnostic Criteria

Differences in healthcare infrastructure, diagnostic methodologies, and reporting systems contribute to substantial variation in prevalence estimates across countries.

Limited Access to Specialists

Shortages of developmental pediatricians, psychologists, neurologists, and behavioral specialists continue delaying diagnosis and comprehensive epidemiological assessment in several regions.

Patient Population and Epidemiology Insights

The global autism spectrum disorder patient population can be segmented by diagnosis status, severity level, age group, gender, and geography.

By diagnosis status, the patient population includes diagnosed patients and undiagnosed patients. Although diagnosed cases continue to increase because of improved awareness and screening, a significant number of individuals remain undiagnosed, particularly in developing healthcare systems.

By severity level, the population includes Level 1 (requiring support), Level 2 (requiring substantial support), and Level 3 (requiring very substantial support). The distribution of patients across severity levels influences healthcare utilization, educational support requirements, and long-term care planning.

By age group, the patient population comprises children, adolescents, and adults. Pediatric patients account for the largest proportion of newly diagnosed cases because autism is generally identified during early childhood, while increasing recognition of adult autism is expanding diagnosis among older populations.

By gender, epidemiological studies consistently report a higher prevalence among males than females, although growing recognition of autism presentations in females is improving diagnostic accuracy and narrowing historical diagnostic gaps.

Patient Population Trends

The global autism patient population continues to evolve as diagnosis improves.

Key trends include:

• Increasing global diagnosed autism population.
• Earlier diagnosis through routine developmental screening.
• Greater identification of autism in adults.
• Improved recognition of autism in females.
• Expansion of national autism surveillance systems.
• Growing use of digital diagnostic technologies.
• Increasing awareness across developing countries.

Regional Insights

North America accounts for one of the largest diagnosed autism populations because of comprehensive screening programs, well-established surveillance systems, advanced healthcare infrastructure, and broad access to developmental specialists.

Europe maintains a substantial patient population through standardized diagnostic guidelines, national healthcare systems, collaborative epidemiological research, and increasing awareness of autism across all age groups.

Asia-Pacific is expected to experience the fastest growth in diagnosed patient populations owing to improving healthcare infrastructure, expanding developmental screening, increasing public awareness, and growing investment in pediatric healthcare services.

Latin America and the Middle East & Africa continue improving autism diagnosis through physician education, expanded screening initiatives, and stronger public health programs, although underdiagnosis remains an important challenge.

Epidemiological Landscape

The epidemiological landscape for autism is increasingly supported by national registries, electronic medical records, school health programs, and population-based surveillance systems. Improvements in data quality are providing more accurate estimates of prevalence, demographic distribution, and healthcare utilization, supporting pharmaceutical research, healthcare planning, and policy development.

Future Outlook

The future of autism spectrum disorder patient population analysis will be driven by continued improvements in developmental screening, earlier diagnosis, artificial intelligence-assisted assessment, and broader implementation of standardized diagnostic criteria. Increasing awareness and stronger epidemiological surveillance are expected to improve identification of previously undiagnosed individuals while supporting development of personalized intervention strategies and future therapeutic innovations.

Conclusion

The Global Autism Spectrum Disorder Patient Population Analysis indicates continued growth in the diagnosed autism population through 2035, supported by expanding awareness, earlier screening, improved diagnostic practices, and stronger epidemiological research. Although regional disparities in diagnosis and healthcare access remain, ongoing advances in surveillance systems, developmental assessment, and public health initiatives are expected to strengthen patient identification and support long-term healthcare planning worldwide.

Key Benefits of this Report

• Comprehensive assessment of the global autism spectrum disorder patient population.
• Detailed analysis of prevalence, demographic trends, and disease burden.
• Evaluation of diagnosis patterns, severity distribution, and regional epidemiology.
• Insights supporting healthcare planning, clinical research, and commercial opportunity assessment.
• Valuable resource for pharmaceutical companies, biotechnology firms, healthcare providers, researchers, policymakers, and investors.

What Businesses Use Our Reports For

Patient population forecasting, epidemiological assessment, healthcare resource planning, clinical trial planning, commercial opportunity evaluation, market access strategy, investment analysis, and long-term strategic decision-making.

Report Coverage

• Historical data from 2021 to 2024, Base Year 2025, and Forecast Period 2026 to 2035
• Comprehensive analysis of the global autism spectrum disorder patient population by diagnosis status, severity level, age group, gender, and geography
• Evaluation of prevalence, incidence, diagnosed and undiagnosed populations, demographic distribution, disease burden, and epidemiological trends
• Assessment of screening programs, diagnostic practices, healthcare utilization, regional disease burden, and future patient population growth
• Analysis of Level 1, Level 2, and Level 3 autism spectrum disorder, pediatric and adult populations, gender distribution, diagnosed and undiagnosed patients, and future epidemiological opportunities through 2035.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Report Scope and Objectives
• 1.2 Key Findings
• 1.3 Patient Population Overview
• 1.4 Epidemiological Highlights
• 1.5 Diagnosed Population Trends
• 1.6 Regional Insights
• 1.7 Key Growth Drivers
• 1.8 Future Outlook (2025-2045)

2. Autism Spectrum Disorder Overview

• 2.1 Introduction to Autism Spectrum Disorder
• 2.2 Disease Definition and Classification
  • 2.2.1 Level 1 ASD (Requiring Support)
  • 2.2.2 Level 2 ASD (Requiring Substantial Support)
  • 2.2.3 Level 3 ASD (Requiring Very Substantial Support)
  • 2.2.4 Syndromic Autism
  • 2.2.5 Non-Syndromic Autism
• 2.3 Disease Pathophysiology
• 2.4 Genetic and Environmental Risk Factors
• 2.5 Clinical Manifestations
• 2.6 Disease Burden
• 2.7 Diagnostic Criteria and Assessment
• 2.8 Patient Journey and Care Pathway

3. Patient Population Methodology

• 3.1 Study Objectives
• 3.2 Population Modeling Framework
• 3.3 Data Sources and Assumptions
• 3.4 Epidemiological Assessment Methodology
• 3.5 Forecasting Methodology (2025-2045)
• 3.6 Data Validation and Triangulation
• 3.7 Limitations and Assumptions

4. Global Autism Spectrum Disorder Patient Population Overview

• 4.1 Total Patient Population
• 4.2 Total Diagnosed Patient Population
• 4.3 Total Treated Patient Population
• 4.4 Total Eligible Patient Population
• 4.5 Diagnosis Rate Analysis
• 4.6 Treatment Rate Analysis
• 4.7 Population Growth Trends
• 4.8 Forecast Analysis (2025-2045)

5. Patient Population Segmentation by Disease Type

• 5.1 Syndromic Autism
  • 5.1.1 Total Patient Population
  • 5.1.2 Diagnosed Population
  • 5.1.3 Treated Population
  • 5.1.4 Forecast Analysis
• 5.2 Non-Syndromic Autism
  • 5.2.1 Total Patient Population
  • 5.2.2 Diagnosed Population
  • 5.2.3 Treated Population
  • 5.2.4 Forecast Analysis

6. Patient Population Segmentation by Disease Severity

• 6.1 Level 1 ASD
  • 6.1.1 Total Patient Population
  • 6.1.2 Diagnosed Population
  • 6.1.3 Treated Population
  • 6.1.4 Forecast Analysis
• 6.2 Level 2 ASD
  • 6.2.1 Total Patient Population
  • 6.2.2 Diagnosed Population
  • 6.2.3 Treated Population
  • 6.2.4 Forecast Analysis
• 6.3 Level 3 ASD
  • 6.3.1 Total Patient Population
  • 6.3.2 Diagnosed Population
  • 6.3.3 Treated Population
  • 6.3.4 Forecast Analysis

7. Patient Population Segmentation by Age Group

• 7.1 Pediatric Population (0-12 Years)
  • 7.1.1 Total Patient Population
  • 7.1.2 Diagnosed Population
  • 7.1.3 Treated Population
  • 7.1.4 Forecast Analysis
• 7.2 Adolescent Population (13-17 Years)
  • 7.2.1 Total Patient Population
  • 7.2.2 Diagnosed Population
  • 7.2.3 Treated Population
  • 7.2.4 Forecast Analysis
• 7.3 Adult Population (18 Years and Above)
  • 7.3.1 Total Patient Population
  • 7.3.2 Diagnosed Population
  • 7.3.3 Treated Population
  • 7.3.4 Forecast Analysis

8. Patient Population Segmentation by Gender

• 8.1 Male Population
  • 8.1.1 Total Patient Population
  • 8.1.2 Diagnosed Population
  • 8.1.3 Treated Population
  • 8.1.4 Forecast Analysis
• 8.2 Female Population
  • 8.2.1 Total Patient Population
  • 8.2.2 Diagnosed Population
  • 8.2.3 Treated Population
  • 8.2.4 Forecast Analysis

9. Diagnosis and Treatment Gap Analysis

• 9.1 Diagnosed versus Undiagnosed Population
• 9.2 Treated versus Untreated Population
• 9.3 Delayed Diagnosis Assessment
• 9.4 Early Diagnosis Trends
• 9.5 Access to Care Assessment
• 9.6 Regional Treatment Gaps
• 9.7 Future Diagnosis Trends
• 9.8 Future Treatment Adoption Trends

10. Geographical Analysis

• 10.1 North America
  • 10.1.1 Total Patient Population
  • 10.1.2 Diagnosed Patient Population
  • 10.1.3 Treated Patient Population
  • 10.1.4 Disease Severity Distribution
  • 10.1.5 Age-Specific Population Analysis
  • 10.1.6 Gender-Specific Population Analysis
  • 10.1.7 Forecast Analysis
• 10.2 Europe
  • 10.2.1 Total Patient Population
  • 10.2.2 Diagnosed Patient Population
  • 10.2.3 Treated Patient Population
  • 10.2.4 Disease Severity Distribution
  • 10.2.5 Age-Specific Population Analysis
  • 10.2.6 Gender-Specific Population Analysis
  • 10.2.7 Forecast Analysis
• 10.3 Asia-Pacific
  • 10.3.1 Total Patient Population
  • 10.3.2 Diagnosed Patient Population
  • 10.3.3 Treated Patient Population
  • 10.3.4 Disease Severity Distribution
  • 10.3.5 Age-Specific Population Analysis
  • 10.3.6 Gender-Specific Population Analysis
  • 10.3.7 Forecast Analysis
• 10.4 Latin America
  • 10.4.1 Total Patient Population
  • 10.4.2 Diagnosed Patient Population
  • 10.4.3 Treated Patient Population
  • 10.4.4 Disease Severity Distribution
  • 10.4.5 Age-Specific Population Analysis
  • 10.4.6 Gender-Specific Population Analysis
  • 10.4.7 Forecast Analysis
• 10.5 Middle East & Africa
  • 10.5.1 Total Patient Population
  • 10.5.2 Diagnosed Patient Population
  • 10.5.3 Treated Patient Population
  • 10.5.4 Disease Severity Distribution
  • 10.5.5 Age-Specific Population Analysis
  • 10.5.6 Gender-Specific Population Analysis
  • 10.5.7 Forecast Analysis

11. Key Countries Analysis

• 11.1 United States
  • 11.1.1 Total Patient Population
  • 11.1.2 Diagnosed Patient Population
  • 11.1.3 Treated Patient Population
  • 11.1.4 Disease Severity Distribution
  • 11.1.5 Age-Specific Population Analysis
  • 11.1.6 Gender-Specific Population Analysis
  • 11.1.7 Forecast Analysis
• 11.2 Canada
  • 11.2.1 Total Patient Population
  • 11.2.2 Diagnosed Patient Population
  • 11.2.3 Treated Patient Population
  • 11.2.4 Disease Severity Distribution
  • 11.2.5 Age-Specific Population Analysis
  • 11.2.6 Gender-Specific Population Analysis
  • 11.2.7 Forecast Analysis
• 11.3 Germany
  • 11.3.1 Total Patient Population
  • 11.3.2 Diagnosed Patient Population
  • 11.3.3 Treated Patient Population
  • 11.3.4 Disease Severity Distribution
  • 11.3.5 Age-Specific Population Analysis
  • 11.3.6 Gender-Specific Population Analysis
  • 11.3.7 Forecast Analysis
• 11.4 United Kingdom
  • 11.4.1 Total Patient Population
  • 11.4.2 Diagnosed Patient Population
  • 11.4.3 Treated Patient Population
  • 11.4.4 Disease Severity Distribution
  • 11.4.5 Age-Specific Population Analysis
  • 11.4.6 Gender-Specific Population Analysis
  • 11.4.7 Forecast Analysis
• 11.5 France
  • 11.5.1 Total Patient Population
  • 11.5.2 Diagnosed Patient Population
  • 11.5.3 Treated Patient Population
  • 11.5.4 Disease Severity Distribution
  • 11.5.5 Age-Specific Population Analysis
  • 11.5.6 Gender-Specific Population Analysis
  • 11.5.7 Forecast Analysis
• 11.6 Italy
  • 11.6.1 Total Patient Population
  • 11.6.2 Diagnosed Patient Population
  • 11.6.3 Treated Patient Population
  • 11.6.4 Disease Severity Distribution
  • 11.6.5 Age-Specific Population Analysis
  • 11.6.6 Gender-Specific Population Analysis
  • 11.6.7 Forecast Analysis
• 11.7 Spain
  • 11.7.1 Total Patient Population
  • 11.7.2 Diagnosed Patient Population
  • 11.7.3 Treated Patient Population
  • 11.7.4 Disease Severity Distribution
  • 11.7.5 Age-Specific Population Analysis
  • 11.7.6 Gender-Specific Population Analysis
  • 11.7.7 Forecast Analysis
• 11.8 China
  • 11.8.1 Total Patient Population
  • 11.8.2 Diagnosed Patient Population
  • 11.8.3 Treated Patient Population
  • 11.8.4 Disease Severity Distribution
  • 11.8.5 Age-Specific Population Analysis
  • 11.8.6 Gender-Specific Population Analysis
  • 11.8.7 Forecast Analysis
• 11.9 Japan
  • 11.9.1 Total Patient Population
  • 11.9.2 Diagnosed Patient Population
  • 11.9.3 Treated Patient Population
  • 11.9.4 Disease Severity Distribution
  • 11.9.5 Age-Specific Population Analysis
  • 11.9.6 Gender-Specific Population Analysis
  • 11.9.7 Forecast Analysis
• 11.10 India
  • 11.10.1 Total Patient Population
  • 11.10.2 Diagnosed Patient Population
  • 11.10.3 Treated Patient Population
  • 11.10.4 Disease Severity Distribution
  • 11.10.5 Age-Specific Population Analysis
  • 11.10.6 Gender-Specific Population Analysis
  • 11.10.7 Forecast Analysis
• 11.11 South Korea
  • 11.11.1 Total Patient Population
  • 11.11.2 Diagnosed Patient Population
  • 11.11.3 Treated Patient Population
  • 11.11.4 Disease Severity Distribution
  • 11.11.5 Age-Specific Population Analysis
  • 11.11.6 Gender-Specific Population Analysis
  • 11.11.7 Forecast Analysis
• 11.12 Australia
  • 11.12.1 Total Patient Population
  • 11.12.2 Diagnosed Patient Population
  • 11.12.3 Treated Patient Population
  • 11.12.4 Disease Severity Distribution
  • 11.12.5 Age-Specific Population Analysis
  • 11.12.6 Gender-Specific Population Analysis
  • 11.12.7 Forecast Analysis

12. Patient Population Forecast Models

• 12.1 Global Patient Population Forecast (2025-2045)
• 12.2 Regional Patient Population Forecast
• 12.3 Country-Level Patient Population Forecast
• 12.4 Disease Severity Forecast Models
• 12.5 Disease Type Forecast Models
• 12.6 Age-Specific Forecast Models
• 12.7 Gender-Specific Forecast Models
• 12.8 Diagnosed Population Forecast Models
• 12.9 Treated Population Forecast Models

13. Company Profiles

• 13.1 Roche
  • 13.1.1 Overview
  • 13.1.2 Financials
  • 13.1.3 Autism Spectrum Disorder Portfolio Overview
  • 13.1.4 Patient Identification Strategy
  • 13.1.5 Target Patient Population Focus
  • 13.1.6 Clinical Development Programs
  • 13.1.7 Commercial Strategy
  • 13.1.8 Recent Developments
• 13.2 Yamo Pharmaceuticals
  • 13.2.1 Overview
  • 13.2.2 Financials
  • 13.2.3 Autism Spectrum Disorder Portfolio Overview
  • 13.2.4 Patient Identification Strategy
  • 13.2.5 Target Patient Population Focus
  • 13.2.6 Clinical Development Programs
  • 13.2.7 Commercial Strategy
  • 13.2.8 Recent Developments
• 13.3 Stalicla SA
  • 13.3.1 Overview
  • 13.3.2 Financials
  • 13.3.3 Autism Spectrum Disorder Portfolio Overview
  • 13.3.4 Precision Patient Stratification Strategy
  • 13.3.5 Target Patient Population Focus
  • 13.3.6 Clinical Development Programs
  • 13.3.7 Commercial Strategy
  • 13.3.8 Recent Developments
• 13.4 Axial Therapeutics
  • 13.4.1 Overview
  • 13.4.2 Financials
  • 13.4.3 Autism Spectrum Disorder Portfolio Overview
  • 13.4.4 Patient Identification Strategy
  • 13.4.5 Target Patient Population Focus
  • 13.4.6 Clinical Development Programs
  • 13.4.7 Commercial Strategy
  • 13.4.8 Recent Developments
• 13.5 SciSparc Ltd.
  • 13.5.1 Overview
  • 13.5.2 Financials
  • 13.5.3 Autism Spectrum Disorder Portfolio Overview
  • 13.5.4 Patient Identification Strategy
  • 13.5.5 Target Patient Population Focus
  • 13.5.6 Clinical Development Programs
  • 13.5.7 Commercial Strategy
  • 13.5.8 Recent Developments
• 13.6 Oryzon Genomics S.A.
  • 13.6.1 Overview
  • 13.6.2 Financials
  • 13.6.3 Autism Spectrum Disorder Portfolio Overview
  • 13.6.4 Patient Identification Strategy
  • 13.6.5 Target Patient Population Focus
  • 13.6.6 Clinical Development Programs
  • 13.6.7 Commercial Strategy
  • 13.6.8 Recent Developments
• 13.7 Curemark, LLC
  • 13.7.1 Overview
  • 13.7.2 Financials
  • 13.7.3 Autism Spectrum Disorder Portfolio Overview
  • 13.7.4 Patient Identification Strategy
  • 13.7.5 Target Patient Population Focus
  • 13.7.6 Clinical Development Programs
  • 13.7.7 Commercial Strategy
  • 13.7.8 Recent Developments
• 13.8 Neurochlore SAS
  • 13.8.1 Overview
  • 13.8.2 Financials
  • 13.8.3 Autism Spectrum Disorder Portfolio Overview
  • 13.8.4 Patient Identification Strategy
  • 13.8.5 Target Patient Population Focus
  • 13.8.6 Clinical Development Programs
  • 13.8.7 Commercial Strategy
  • 13.8.8 Recent Developments
• 13.9 Jazz Pharmaceuticals plc
  • 13.9.1 Overview
  • 13.9.2 Financials
  • 13.9.3 Autism Spectrum Disorder Portfolio Overview
  • 13.9.4 Patient Identification Strategy
  • 13.9.5 Target Patient Population Focus
  • 13.9.6 Clinical Development Programs
  • 13.9.7 Commercial Strategy
  • 13.9.8 Recent Developments
• 13.10 Servier
  • 13.10.1 Overview
  • 13.10.2 Financials
  • 13.10.3 Autism Spectrum Disorder Portfolio Overview
  • 13.10.4 Patient Identification Strategy
  • 13.10.5 Target Patient Population Focus
  • 13.10.6 Clinical Development Programs
  • 13.10.7 Commercial Strategy
  • 13.10.8 Recent Developments

14. Key Opinion Leader (KOL) Insights

• 14.1 Patient Population Trends
• 14.2 Diagnostic Trends and Challenges
• 14.3 Disease Awareness Trends
• 14.4 Future Population Growth Drivers
• 14.5 Expert Perspectives on ASD Burden

15. Research Methodology

• 15.1 Primary Research
• 15.2 Secondary Research
• 15.3 Patient Population Modeling Methodology
• 15.4 Forecasting Methodology
• 15.5 Data Validation and Triangulation
• 15.6 Assumptions and Limitations

16. Appendix

• 16.1 Abbreviations
• 16.2 Glossary of Terms
• 16.3 References
• 16.4 List of Tables
• 16.5 List of Figures
• 16.6 Epidemiology Databases
• 16.7 Clinical Literature Sources
• 16.8 Company Sources
• 16.9 Healthcare Organization Sources